6. Bio-Driven Economy: BRIC-RGCB’s New Frontier in Biotechnology

• Infrastructure Milestone: The inauguration of the Central Facility for Recombinant Cells and Sensors at BRIC-RGCB, Thiruvananthapuram (costing ₹60 crore), marks a major leap in India\'s drug discovery and genomics capabilities. It houses engineered cells and advanced screening systems to serve as a national hub for academia and industry. • BioE3 Policy & Biomanufacturing: The government is leveraging the BioE3 Policy (Economy, Environment, and Employment) to transition India toward a $300 billion bioeconomy. This policy focuses on high-performance biomanufacturing to drive sustainable growth and climate-resilient agriculture. • Exponential Startup Growth: India\'s biotechnology ecosystem has witnessed a tectonic shift, growing from roughly 50 startups in 2014 to over 11,000 in 2026. This 16-fold expansion in the bioeconomy (from $10 billion to $166 billion in a decade) reflects robust policy support and deep-tech funding. • Advancements in Cell Therapy: A new GMP (Good Manufacturing Practice) facility (₹80 crore) is being established at BRIC-RGCB to bridge the gap between lab research and commercial production of biologics. It will specifically boost CAR-T cell therapy and other advanced cell-based treatments for cancer. • Strategic Convergence: The facility aligns with national missions in Agri-Genomics (to enhance crop resilience) and Medical Genomics (to tackle rising non-communicable diseases like cancer and diabetes). It also promotes \'pay-and-use\' models for private industry to foster innovation. • Health & Preventive Research: The center\'s focus on cancer biology (oral, breast, cervical) and HPV vaccination research supports India’s broader public health goals, emphasizing that advanced research must translate into affordable preventive healthcare outcomes. Key Definitions • Recombinant Cells: Cells that have been genetically altered by introducing foreign DNA to produce specific proteins or study disease mechanisms. • Bioeconomy: An economic model based on the sustainable use of biological resources (plants, animals, microorganisms) to produce food, energy, and industrial goods. • GMP Facility: A system for ensuring that products are consistently produced and controlled according to quality standards, essential for pharmaceutical and cell-therapy manufacturing. • CAR-T Therapy: Chimeric Antigen Receptor T-cell therapy; a type of immunotherapy where a patient\'s T-cells are reprogrammed in a lab to find and destroy cancer cells. Constitutional & Legal Provisions • Article 51A(h): Part of Fundamental Duties, it mandates every citizen to develop \'scientific temper, humanism and the spirit of inquiry and reform.\' • Article 39(f): Directive Principles of State Policy (DPSP) emphasize that childhood and youth are protected against exploitation; research in pediatric genomics and preventive vaccines aligns with this. • The Biological Diversity Act, 2002: Regulates access to biological resources and ensures equitable sharing of benefits, which is central to India\'s growing bio-driven economy. • BioE3 Policy (2024): A landmark executive policy framework by the Department of Biotechnology (DBT) to promote high-performance biomanufacturing in India. Additional Key Pillars • Deep-Tech Incentives: The government is providing dedicated funding for startups involved in complex technologies like synthetic biology and precision medicine. • National Science Day Connection: The facility was inaugurated on February 28 (National Science Day), commemorating the discovery of the Raman Effect and emphasizing \'Indigenous Technologies for Viksit Bharat.\' • Marine Biotechnology: Encouragement for coastal institutions like BRIC-RGCB to link biotech research with marine biodiversity and fisheries for blue-economy growth. Conclusion The establishment of the Central Facility for Recombinant Cells and Sensors signifies India\'s shift from being a biotechnology consumer to a global innovation leader. By integrating cutting-edge research in cell biology with a robust biomanufacturing policy (BioE3), India is creating a self-reliant (Atmanirbhar) ecosystem. This infrastructure not only promises breakthroughs in life-saving cancer therapies like CAR-T but also secures the nation’s future in agricultural productivity and environmental sustainability through agri-genomics. UPSC Relevance • GS Paper III: Science and Technology- developments and their applications and effects in everyday life; Awareness in the fields of IT, Space, Computers, Robotics, Nanotechnology, and Biotechnology. • GS Paper III: Issues relating to intellectual property rights; Indian Economy (Bioeconomy growth and startup ecosystem). • Prelims: BRIC (Biotechnology Research and Innovation Council); BioE3 Policy targets; CAR-T therapy mechanisms; National Science Day significance.